Donor administration of PAF antagonist (TCV-309) enhances lung preservation.
Ide
S
S
First Department of Surgery, Nagasaki University School of Medicine, Japan.
Kawahara
K
K
Takahashi
T
T
Sasaki
N
N
Shingu
H
H
Nagayasu
T
T
Yamamoto
S
S
Tagawa
T
T
Tomita
M
M
D000818:Animals; D002245:Carbon Dioxide / Q000097:blood; D004285:Dogs; D007546:Isoquinolines / Q000494:pharmacology*; D008168:Lung / Q000187:drug effects; D016040:Lung Transplantation / Q000473:pathology / Q000502:physiology*; D009926:Organ Preservation / Q000379:methods*; D010100:Oxygen / Q000097:blood; D010313:Partial Pressure; D009195:Peroxidase / Q000032:analysis; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors*; D011651:Pulmonary Artery / Q000502:physiology; D011667:Pulmonary Veins / Q000502:physiology; D011726:Pyridinium Compounds / Q000494:pharmacology*; D015424:Reperfusion; D015427:Reperfusion Injury / Q000517:prevention & control*; D044005:Tetrahydroisoquinolines
D007546:Isoquinolines; D010972:Platelet Activating Factor; D011726:Pyridinium Compounds; D044005:Tetrahydroisoquinolines; D002245:Carbon Dioxide; D009195:Peroxidase; D010100:Oxygen; C067430:TCV 309